Grateful to mark ULab’s 3rd birthday surrounded by brilliant minds and a deep sense of belonging. In a time of shifting priorities in academia, I’m especially thankful for the inclusive leadership and unwavering support of my incredible PI, Jessalyn @ubellackerlab.bsky.social
Interested in studying lymph node metastasis? Check out our protocol by Cort Breuer out today in @natprot.nature.com
bsky.app/profile/nat...
Thanks to James Olzmann and Scott Dixon for organizing a fantastic #faseb #ferroptosis meeting in Scottsdale AZ! Lots of great science as ferroptosis continues to impact diverse biology and diseases. Can’t wait for the next one! @olzmannlab.bsky.social
Marie Sabatier
In Wiley Advanced Science @mariesabatier.bsky.social, @ubellackerlab.bsky.social, and colleagues examine GPX4 inhibitor resistance in triple-negative breast cancer, showing that resistant cells survive in circulation but lose the ability to spontaneously metastasize from primary tumors. hsph.me/GPX4
Nathan Reticker-Flynn
Excited to share my postdoctoral work, out today in Nature! www.nature.com/articles/s41...
We discovered that melanoma cells in lymph nodes gain a targetable FSP1 dependency that limits melanoma progression.
Way-to-go Alanis Carmona and Lewis Hendrianto for your incredible posters today at the Landry Cancer Biology Consortium, and shout-out to Alanis on your Karin Grunebaum Cancer Research Foundation Rising Young Scientist Award!
Happy to see our News & Views is out! We highlight two landmark papers demonstrating the potential for therapeutic targeting of FSP1 and #ferroptosis in in vivo cancer models. Beautiful work from @ubellackerlab.bsky.social, Thales Papagiannakopoulos, and colleagues. 🥳
www.nature.com/articles/s41...
Join me in Boston October 6th for a 1-day conference on #mappingbiology to transform #cancertherapeutics. Register by September 25th to benefit from the complimentary (free) admission! Topics, speakers, and talk opportunities here: abcam.me/mappingbiolo...
@abcamofficial.bsky.social
Hot off the presses! Was an honor to team up with Scott Dixon @stanforduniversity.bsky.social on this Nature Cancer review. We reflect on hurdles that have slowed translation of ferroptosis-directed therapies and share ideas on what it will take to bring these therapies to the clinic. rdcu.be/eBbqV
Excited to share our work @nature.com! Postdoc @mariopalma.bsky.social, with major contributions from @retickerflynn.bsky.social and collaborators, discovered melanoma cells in lymph nodes gain a targetable FSP1 dependency that limits progression. #TeamFSP1
www.nature.com/articles/s41...
Brent Stockwell
Targeting FSP1 in lymph nodes has considerable potential for blocking melanoma progression.
FSP1 is a key suppressor of lipid peroxidation and ferroptosis, yet it is largely dispensable in standard cell culture models. Two new studies now show that FSP1 becomes essential for tumour growth in...
It’s over 100°F in Boston, and though both the weather and funding climates are intense, we took a well-deserved ice cream break to celebrate the progress, and the incredible people past and present, behind it all. Happy 3rd birthday, ULab! 🎉
Ubellacker Lab
Ubellacker Lab
Nature Cancer - Ubellacker and Dixon summarize the latest discoveries on ferroptosis in cancer, covering the molecular and cellular pathways underlying sensitivity and resistance to this type of...
New Article! Spontaneous and experimental models of lymph node metastasis
https://bit.ly/4fzWoAj
bsky.app
James Olzmann
Ubellacker Lab
Ferroptosis-targeting therapies in cancer have yet to make it to the clinic. New review published today in Nature Cancer by @ubellackerlab.bsky.social and Scott Dixon of Stanford share hurdles and ideas for future strategies to bring these therapies closer to the clinic. Check it out
rdcu.be/eBbqV
Nature Cancer - Ubellacker and Dixon summarize the latest discoveries on ferroptosis in cancer, covering the molecular and cellular pathways underlying sensitivity and resistance to this type of...
